Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.
NCT ID: NCT01890291
Last Updated: 2023-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
162 participants
OBSERVATIONAL
2013-06-30
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma
NCT02482909
Dual and Single Switching Monopolar RFA Using Separable Clustered Electrode for Treatment of HCC
NCT03699657
Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
NCT01490203
Anatomical Radiofrequency Ablation for Small Hepatocellular Carcinoma
NCT05580224
RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode
NCT02806076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-treatment Group
Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
No interventions assigned to this group
Immuncell-LC Group
Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients of participated in the(ClinicalTrials.gov Identifier:NCT00699816)clinical trial.
Exclusion Criteria
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GC Cell Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jung Hwan Yoon, MD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Joon Hyeok Lee, MD
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Young-Suk Lim, MD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Tae Gin Song, MD
Role: PRINCIPAL_INVESTIGATOR
Korea University Ansan Hospital
Jong Eun Yeon, MD
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Korea University Ansan Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIC-I02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.